176 related articles for article (PubMed ID: 24204700)
1. Extracellular high mobility group box 1 plays a role in the effect of bone marrow mononuclear cell transplantation for heart failure.
Kaneko M; Shintani Y; Narita T; Ikebe C; Tano N; Yamahara K; Fukushima S; Coppen SR; Suzuki K
PLoS One; 2013; 8(10):e76908. PubMed ID: 24204700
[TBL] [Abstract][Full Text] [Related]
2. Donor cell-type specific paracrine effects of cell transplantation for post-infarction heart failure.
Shintani Y; Fukushima S; Varela-Carver A; Lee J; Coppen SR; Takahashi K; Brouilette SW; Yashiro K; Terracciano CM; Yacoub MH; Suzuki K
J Mol Cell Cardiol; 2009 Aug; 47(2):288-95. PubMed ID: 19467239
[TBL] [Abstract][Full Text] [Related]
3. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart.
Takahashi K; Fukushima S; Yamahara K; Yashiro K; Shintani Y; Coppen SR; Salem HK; Brouilette SW; Yacoub MH; Suzuki K
Circulation; 2008 Sep; 118(14 Suppl):S106-14. PubMed ID: 18824741
[TBL] [Abstract][Full Text] [Related]
4. A factor underlying late-phase arrhythmogenicity after cell therapy to the heart: global downregulation of connexin43 in the host myocardium after skeletal myoblast transplantation.
Coppen SR; Fukushima S; Shintani Y; Takahashi K; Varela-Carver A; Salem H; Yashiro K; Yacoub MH; Suzuki K
Circulation; 2008 Sep; 118(14 Suppl):S138-44. PubMed ID: 18824745
[TBL] [Abstract][Full Text] [Related]
5. Comparison of intramyocardial and intravenous routes of delivering bone marrow cells for the treatment of ischemic heart disease: an experimental study.
Hayashi M; Li TS; Ito H; Mikamo A; Hamano K
Cell Transplant; 2004; 13(6):639-47. PubMed ID: 15648734
[TBL] [Abstract][Full Text] [Related]
6. Timing of bone marrow cell delivery has minimal effects on cell viability and cardiac recovery after myocardial infarction.
Swijnenburg RJ; Govaert JA; van der Bogt KE; Pearl JI; Huang M; Stein W; Hoyt G; Vogel H; Contag CH; Robbins RC; Wu JC
Circ Cardiovasc Imaging; 2010 Jan; 3(1):77-85. PubMed ID: 19920031
[TBL] [Abstract][Full Text] [Related]
7. Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival.
Spiegelstein D; Kim C; Zhang Y; Li G; Weisel RD; Li RK; Yau TM
Am J Physiol Heart Circ Physiol; 2007 Dec; 293(6):H3311-6. PubMed ID: 17827264
[TBL] [Abstract][Full Text] [Related]
8. Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure.
Zhang L; Liu M; Jiang H; Yu Y; Yu P; Tong R; Wu J; Zhang S; Yao K; Zou Y; Ge J
J Cell Mol Med; 2016 Mar; 20(3):459-70. PubMed ID: 26647902
[TBL] [Abstract][Full Text] [Related]
9. Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model.
Zhu H; Li J; Wang S; Liu K; Wang L; Huang L
Transplantation; 2013 Jun; 95(12):1448-54. PubMed ID: 23677049
[TBL] [Abstract][Full Text] [Related]
10. High Mobility Group Box 1 Promotes Angiogenesis from Bone Marrow-derived Endothelial Progenitor Cells after Myocardial Infarction.
Nakamura Y; Suzuki S; Shimizu T; Miyata M; Shishido T; Ikeda K; Saitoh S; Kubota I; Takeishi Y
J Atheroscler Thromb; 2015; 22(6):570-81. PubMed ID: 25735431
[TBL] [Abstract][Full Text] [Related]
11. Cardiac effects of experimental intravenous bone marrow cell transplantation after myocardial infarction.
Holinski S; Heinze G; Knebel F; Borges AC; Baumann G; Rudolph B; Konertz W
Ann Thorac Cardiovasc Surg; 2012; 18(5):452-7. PubMed ID: 22673555
[TBL] [Abstract][Full Text] [Related]
12. Maximizing ventricular function with multimodal cell-based gene therapy.
Yau TM; Kim C; Li G; Zhang Y; Weisel RD; Li RK
Circulation; 2005 Aug; 112(9 Suppl):I123-8. PubMed ID: 16159803
[TBL] [Abstract][Full Text] [Related]
13. Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells.
Quijada P; Toko H; Fischer KM; Bailey B; Reilly P; Hunt KD; Gude NA; Avitabile D; Sussman MA
Circ Res; 2012 Jun; 111(1):77-86. PubMed ID: 22619278
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease.
van Koppen A; Papazova DA; Oosterhuis NR; Gremmels H; Giles RH; Fledderus JO; Joles JA; Verhaar MC
Stem Cell Res Ther; 2015 Apr; 6(1):63. PubMed ID: 25889756
[TBL] [Abstract][Full Text] [Related]
15. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling.
Kohno T; Anzai T; Naito K; Miyasho T; Okamoto M; Yokota H; Yamada S; Maekawa Y; Takahashi T; Yoshikawa T; Ishizaka A; Ogawa S
Cardiovasc Res; 2009 Feb; 81(3):565-73. PubMed ID: 18984601
[TBL] [Abstract][Full Text] [Related]
16. Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning.
Ito A; Ito T; Kamiike W; Moriguchi A; Ohkawa A; Uchikoshi F; Tanaka S; Nakata S; Matsuda H
Transplantation; 1997 Sep; 64(5):752-7. PubMed ID: 9311715
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow mononuclear cell transplantation into heart elevates the expression of angiogenic factors.
Liu Y; Guo J; Zhang P; Zhang S; Chen P; Ma K; Zhou C
Microvasc Res; 2004 Nov; 68(3):156-60. PubMed ID: 15501234
[TBL] [Abstract][Full Text] [Related]
18. Age-related defects in autophagy alter the secretion of paracrine factors from bone marrow mononuclear cells.
Yeganeh A; Alibhai FJ; Tobin SW; Lim F; Wu J; Li S; Weisel RD; Li RK
Aging (Albany NY); 2021 Jun; 13(11):14687-14708. PubMed ID: 34088884
[TBL] [Abstract][Full Text] [Related]
19. High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages.
Vacas S; Degos V; Tracey KJ; Maze M
Anesthesiology; 2014 May; 120(5):1160-7. PubMed ID: 24162463
[TBL] [Abstract][Full Text] [Related]
20. The administration of high-mobility group box 1 fragment prevents deterioration of cardiac performance by enhancement of bone marrow mesenchymal stem cell homing in the delta-sarcoglycan-deficient hamster.
Kido T; Miyagawa S; Goto T; Tamai K; Ueno T; Toda K; Kuratani T; Sawa Y
PLoS One; 2018; 13(12):e0202838. PubMed ID: 30517097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
